These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Multi-functional nanocarriers based on iron oxide nanoparticles conjugated with doxorubicin, poly(ethylene glycol) and folic acid as theranostics for cancer therapy.
    Author: Rajkumar S, Prabaharan M.
    Journal: Colloids Surf B Biointerfaces; 2018 Oct 01; 170():529-537. PubMed ID: 29966906.
    Abstract:
    Multi-functional nanocarriers based on iron oxide nanoparticles (IONPs) conjugated with doxorubicin (DOX), poly(ethylene glycol) (PEG), and folic acid (FA) (IO-MMA-DOX-PEG-OCH3/FA) were prepared as theranostics for cancer therapy. Using mono-methyl adipate (MMA) as a linker, the anticancer drug, DOX, was conjugated on the surface of IONPs by acid-cleavable hydrazone bond. The average size of the IO-MMA-DOX-PEG-OCH3/FA nanocarriers was determined as 14 and 40 nm by TEM and DLS, respectively. The saturation magnetization (Ms) and transverse relaxivity (r2) value of IO-MMA-DOX-PEG-OCH3/FA nanocarriers were calculated as 28.62 Am2/kg and 133 mM-1s-1, respectively. The rate and amount of DOX released from the IO-MMA-DOX-PEG-OCH3/FA nanocarriers were higher at acidic medium (pH 5.6) than that at alkaline medium (pH 7.4) due to the presence of hydrazone bond between the DOX and IONPs. The IO-MMA-DOX-PEG-OCH3/FA nanocarriers showed the higher cellular uptake than FA-free nanocarriers due to the folate-receptor-mediated endocytosis, thereby presenting an enhanced cytotoxicity against folate-receptor-positive HeLa cells through apoptosis. The results confirmed that the IO-MMA-DOX-PEG-OCH3/FA nanocarriers could be promising for cancer therapy with the improved drug loading, tumor-targeted controlled drug release and MRI abilities.
    [Abstract] [Full Text] [Related] [New Search]